Liberty One Investment Management LLC Has $8.68 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Liberty One Investment Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 93,962 shares of the biopharmaceutical company’s stock after selling 7,350 shares during the period. Gilead Sciences comprises approximately 0.9% of Liberty One Investment Management LLC’s holdings, making the stock its 25th largest position. Liberty One Investment Management LLC’s holdings in Gilead Sciences were worth $8,679,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in GILD. Massachusetts Financial Services Co. MA grew its holdings in Gilead Sciences by 0.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after buying an additional 522 shares in the last quarter. Seven Eight Capital LP purchased a new position in Gilead Sciences during the 2nd quarter worth $525,000. MQS Management LLC grew its stake in shares of Gilead Sciences by 33.9% in the 2nd quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 1,157 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of Gilead Sciences by 3.7% in the second quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock valued at $4,749,000 after purchasing an additional 2,453 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Gilead Sciences by 91.4% during the second quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company’s stock valued at $185,238,000 after purchasing an additional 1,289,420 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Oppenheimer upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Finally, Truist Financial boosted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Trading Up 0.2 %

Shares of Gilead Sciences stock opened at $91.84 on Friday. The company has a 50 day simple moving average of $91.75 and a two-hundred day simple moving average of $83.97. The firm has a market cap of $114.46 billion, a PE ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.